18 February 2016 - AstraZeneca today announced that the European Commission has granted marketing authorisation for Zurampic (lesinurad) 200 mg in combination with a xanthine oxidase inhibitor (XOI) for the adjunctive treatment of hyperuricemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid (sUA) levels with an adequate dose of an XOI alone.

For more details, go to: https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/zurampic-lesinurad-approved-in-the-european-union-for-patients-with-gout-19022016.html